Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
Portfolio Pulse from
Senti Biosciences (SNTI) announced financial results for Q4 2024, highlighting key achievements including MRD negative clinical response in 2 of 3 relapsed/refractory AML patients in their Phase 1 trial of SENTI-202. The company also raised approximately $47.6 million through a private investment in public equity (PIPE) financing, bolstering its balance sheet.
March 20, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive early-stage clinical trial results for SENTI-202 in AML and successful capital raise indicate potential growth and development for the company.
Positive clinical trial results, successful financing, and advancement of proprietary Gene Circuit platform suggest potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100